Bulimia nervosa also known as bulimia is an eating disorder associated with binge eating that follow the compensatory procedures. Patients suffering from this illness have repeat episodes of binge eating which may involve eating significantly larger portions of food than a normal individual within the same duration and under similar circumstances; and a lack of control over eating during that duration. This is followed by recurrent behavior to prevent weight gain such as excessive usage of medications such as laxatives and diuretics; excessive fasting; excessive exercise; and self-induced vomiting among others. This continuous cycle of binge eating and purging impacts the physical and mental well-being of the individual. Furthermore, it causes damage to the digestive system and causes chemical imbalances in the body, impacting the functioning of major body organs such as the heart, which could prove to be fatal. A range of factors are responsible for causing bulimia nervosa, which include emotional distress, growing stress, low confidence, and frequent concerns over weight gain. The symptoms associated with bulimia nervosa include dislike of one’s physical appearance, guilt feelings, anxiety, depression, obsessive compulsive disorder, and substance use, among others. However, most of these symptoms are unnoticed in the individual, making it difficult to diagnose the disease.

Bulimia nervosa is more commonly observed among women as compared to men. The lifetime prevalence of the disease in the U.S. is found to be over 1.5% of women and 0.5% of men which translates to over 4.5 million women and 1.5 million men. This disease is found to be common among adolescents; however, it has also been diagnosed in patients as young as six years and in older adults. The increasing intake of alcohol and increasing number of cardio-vascular diseases which lead to bulimia nervosa among patients is likely to contribute to the growth of the market during the forecast period. However, the high cost of treatment, and the lack of drugs specific to the treatment of bulimia nervosa might have an adverse effect on future market growth.

The bulimia nervosa market can be segmented based on treatment type, distribution channel, and geography. On the basis of treatment type, the market can be segmented into medications, which include prescription drugs; psychotherapies, nutritional therapies, and other non-drug therapies. Prescription drugs can be further segmented into antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tetracyclic antidepressants, opioid antagonists, and others. Prescription drug therapy primarily employed for the treatment of the disease are aimed at treatment of depression, anxiety, or obsessive-compulsive disorder, which often co-exist along with bulimia nervosa. Some of the prescription drugs are intended to induce the feeling of fullness in the individual to prevent binge eating. In addition, there is one prescription drug, fluoxetine, which has been approved by the U.S. FDA specifically for bulimia nervosa indication. On the basis of distribution channel, the market can be segmented into hospital pharmacies, and retail pharmacies, among others. Hospital pharmacies are anticipated to be the leading segment in the bulimia nervosa market.

Geographically, the bulimia nervosa market can be segmented into five regions, including North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to record highest share in the market owing to the growing incidence and prevalence of the disease; focus of various organizations to create awareness among people; and due to a well-developed healthcare infrastructure. Europe is anticipated to follow North America in the bulimia nervosa market. However, growth in the region is anticipated to be negatively impacted owing to the sluggish economic growth in the region. Asia Pacific is expected to record a robust CAGR during the forecast period, owing to significant contribution from emerging countries such as China and India.

The leading players in the bulimia nervosa market include Eli Lilly and Company, AstraZeneca, Forest Pharmaceuticals, Inc., Pfizer, Inc., Bristol-Myers Squibb, Johnson & Johnson, and GlaxoSmithKline.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Bulimia Nervosa Market

Pre Book